A phase I/II open label, multi-center, dose-escalation study of subcutaneous CPG 7909 plus Herceptin in patients with metastatic breast cancer.

Trial Profile

A phase I/II open label, multi-center, dose-escalation study of subcutaneous CPG 7909 plus Herceptin in patients with metastatic breast cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Mar 2009

At a glance

  • Drugs Agatolimod; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Mar 2009 Actual patient number (16) added as reported by ClinicalTrials.gov.
    • 20 Jun 2007 Pfizer has discontinued the PF-3512676 development programme because of no evidence of additional clinical efficacy compared with standard antineoplastics alone.
    • 14 Oct 2005 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top